RET proto-oncogene testing in infants presenting with Hirschsprung disease identifies 2 new multiple endocrine neoplasia 2A kindreds

被引:19
作者
Fialkowski, Elizabeth A. [1 ]
DeBenedetti, Mary K. [1 ]
Moley, Jeffrey F. [1 ]
Bachrach, Bert [2 ]
机构
[1] Washington Univ, Sch Med, St Louis, MO 63110 USA
[2] Univ Missouri, Childrens Hosp, Columbia, MO 65203 USA
关键词
multiple endocrine neoplasia; Hirschsprung disease; RET proto-oncogene; medullary thyroid carcinoma;
D O I
10.1016/j.jpedsurg.2007.09.043
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background: Multiple endocrine neoplasia 2A (MEN 2A) is a genetic syndrome manifesting as medullary thyroid carcinoma (MTC), hyperparathyroidism, and pheochromocytoma. Multiple endocrine neoplasia 2A results from mutations in the RET proto-oncogene. Hirschsprung disease (HSCR) is a rare manifestation of MEN 2A and has been described in known MEN 2A families. Methods: Here we describe 2 MEN 2A families that were only identified after the diagnosis of HSCR. Results: Kindred 1: A boy presented in infancy with HSCR. Genetic screening revealed a C609Y mutation, which is consistent with MEN 2A. Evaluation of his sister, father, and grandmother revealed the same mutation. All 3 had thyroidectomies demonstrating C-cell hyperplasia. The grandmother had a microscopic focus of MTC.Kindred 2: An infant boy and his sister were diagnosed with HSCR as neonates. Genetic testing demonstrated a C620R gene mutation consistent with MEN 2A. Total thyroidectomies revealed metastatic MTC in the father and C-cell hyperplasia in both children. Conclusions: Hirschsprung disease can be the initial presentation of MEN 2A. We strongly recommend that genetic screening be performed in patients presenting with HSCR, looking for the known RET mutations associated with MEN 2A. If a mutation consistent with MEN 2A is detected, genetic screening of all first-degree relatives in the kindred is recommended. (C) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:188 / 190
页数:3
相关论文
共 33 条
[1]   DIVERSITY OF RET PROTOONCOGENE MUTATIONS IN FAMILIAL AND SPORADIC HIRSCHSPRUNG DISEASE [J].
ATTIE, T ;
PELET, A ;
EDERY, P ;
ENG, C ;
MULLIGAN, LM ;
AMIEL, J ;
BOUTRAND, L ;
BELDJORD, C ;
NIHOULFEKETE, C ;
MUNNICH, A ;
PONDER, BAJ ;
LYONNET, S .
HUMAN MOLECULAR GENETICS, 1995, 4 (08) :1381-1386
[2]  
AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305
[3]  
BLOCK MA, 1980, ARCH SURG-CHICAGO, V115, P142
[4]   Guidelines for diagnosis and therapy of MEN type 1 and type 2 [J].
Brandi, ML ;
Gagel, RF ;
Angeli, A ;
Bilezikian, JP ;
Beck-Peccoz, P ;
Bordi, C ;
Conte-Devolx, B ;
Falchetti, A ;
Gheri, RG ;
Libroia, A ;
Lips, CJM ;
Lombardi, G ;
Mannelli, M ;
Pacini, F ;
Pondder, BAJ ;
Raue, F ;
Skogseid, B ;
Tamburrano, G ;
Thakker, RV ;
Thompson, NW ;
Tomassetti, P ;
Tonelli, F ;
Wells, SA ;
Marx, SJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (12) :5658-5671
[5]   Advances in ontogeny of the enteric nervous system [J].
Burns, A. J. ;
Thapar, N. .
NEUROGASTROENTEROLOGY AND MOTILITY, 2006, 18 (10) :876-887
[6]   Occurrence of MEN 2a in familial Hirschsprung's disease:: A new indication for genetic testing of the RET proto-oncogene [J].
Decker, RA ;
Peacock, ML .
JOURNAL OF PEDIATRIC SURGERY, 1998, 33 (02) :207-213
[7]   Hirschsprung disease in MEN 2A:: increased spectrum of RET exon 10 genotypes and strong genotype-phenotype correlation [J].
Decker, RA ;
Peacock, ML ;
Watson, P .
HUMAN MOLECULAR GENETICS, 1998, 7 (01) :129-134
[8]   MUTATIONS IN THE RET PROTOONCOGENE ARE ASSOCIATED WITH MEN 2A AND FMTC [J].
DONISKELLER, H ;
DOU, SS ;
CHI, D ;
CARLSON, KM ;
TOSHIMA, K ;
LAIRMORE, TC ;
HOWE, JR ;
MOLEY, JF ;
GOODFELLOW, P ;
WELLS, SA .
HUMAN MOLECULAR GENETICS, 1993, 2 (07) :851-856
[9]   MUTATIONS OF THE RET PROTOONCOGENE IN HIRSCHSPRUNGS-DISEASE [J].
EDERY, P ;
LYONNET, S ;
MULLIGAN, LM ;
PELET, A ;
DOW, E ;
ABEL, L ;
HOLDER, S ;
NIHOULFEKETE, C ;
PONDER, BAJ ;
MUNNICH, A .
NATURE, 1994, 367 (6461) :378-380
[10]   RET proto-oncogene in the development of human cancer [J].
Eng, C .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :380-393